NCT06486909 Shunt-dependency After aSAH - Role of Early Hyperglycaemia in CSF and Blood
| NCT ID | NCT06486909 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Isabel Hostettler |
| Condition | Aneurysm, Ruptured |
| Study Type | OBSERVATIONAL |
| Enrollment | 160 participants |
| Start Date | 2024-03-26 |
| Primary Completion | 2027-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 160 participants in total. It began in 2024-03-26 with a primary completion date of 2027-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to confirm the association of early increased glucose levels in cerebro-spinal fluid (CSF) and ventriculo-peritoneal-shunt (VPS)-dependency also evaluating the influence of blood glucose on VPS dependency in patients suffering from an aneurysmal subarachnoid haemorrhage (aSAH). The main questions we aim to answer are: * Is there an association of glucose levels on VPS dependency in patients requiring extra-ventricular-drain (EVD) placement for aSAH? * In addition, if there is, what is the influence the course of glucose levels has on VPS dependency? Glucose levels in CSF and serum will be measured on admission, or in case of CSF, upon EVD placement. Glucose in CSF will then be measured every day until EVD removal together with serum glucose. Follow-up will be conducted in person after 3 and 6 months.
Eligibility Criteria
Inclusion Criteria: * 18 years old and older * Hospital admission due to an aneurysmal subarachnoid haemorrhage (radiological confirmation needed) Exclusion Criteria: * Younger than 18 years old * Non-aneurysmal subarachnoid haemorrhage (eg. trauma, perimesencephalic subarachnoid haemorrhage, mycotic or flow-associated aneurysms) * Previous enrolment into the current study
Contact & Investigator
Isabel Hostettler, MD PhD
PRINCIPAL INVESTIGATOR
Cantonal Hospital of St. Gallen
Frequently Asked Questions
Who can join the NCT06486909 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Aneurysm, Ruptured. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06486909 currently recruiting?
Yes, NCT06486909 is actively recruiting participants. Contact the research team at isabel.hostettler@kssg.ch for enrollment information.
Where is the NCT06486909 trial being conducted?
This trial is being conducted at Aarau, Switzerland, Basel, Switzerland, Sankt Gallen, Switzerland.
Who is sponsoring the NCT06486909 clinical trial?
NCT06486909 is sponsored by Isabel Hostettler. The principal investigator is Isabel Hostettler, MD PhD at Cantonal Hospital of St. Gallen. The trial plans to enroll 160 participants.